BEECH研究:AKT抑制剂卡匹伐替尼联合紫杉醇治疗雌激素受体阳性晚期或转移性乳腺癌及PIK3CA突变亚组的剂量探索导入后随机II期研究
BEECH研究含Ib期安全性导入(38例晚期乳腺癌)和随机双盲II期扩展(110例ER+/HER2-转移性乳腺癌)。导入期确定卡匹伐替尼400mg每日两次、用4天停3天方案;II期总体人群中位无进展生存期卡匹伐替尼组10.9个月 vs 安慰剂组8.4个月(HR 0.80,P=0.308),PIK3CA突变亚组10.9个月 vs 10.8个月(HR 1.11,P=0.760)。结论:卡匹伐替尼未延长无进展生存期。
要点
- 导入期确定卡匹伐替尼400mg每日两次、用4天停3天的给药方案。
- 总体人群中位无进展生存期卡匹伐替尼组10.9个月 vs 安慰剂组8.4个月(HR 0.80,P=0.308)。
- PIK3CA突变亚组中位无进展生存期卡匹伐替尼组10.9个月 vs 安慰剂组10.8个月(HR 1.11,P=0.760)。
核心结论
- 卡匹伐替尼对紫杉醇的耐受性和剂量强度无明显影响。
- 在总体人群和PIK3CA突变亚组中,卡匹伐替尼联合每周紫杉醇均未延长无进展生存期。
研究设计与样本
- BEECH研究包括开放标签Ib期安全性导入(A部分,38例晚期乳腺癌患者)和随机、安慰剂对照、双盲II期扩展(B部分,110例ER+/HER2-转移性乳腺癌女性患者)。
- A部分患者接受紫杉醇90 mg/m2(28天周期第1、8、15天)联合卡匹伐替尼每日两次,采用两种间歇递增给药方案。
- B部分患者按PIK3CA突变状态分层随机,接受紫杉醇联合卡匹伐替尼或安慰剂。
- A部分主要终点为安全性,以推荐B部分剂量和方案;B部分主要终点为总体人群和PIK3CA+亚组的无进展生存期。
主要发现
- 卡匹伐替尼耐受性良好,A部分选定400 mg每日两次、用4天停3天的给药方案。
- B部分总体人群中位无进展生存期卡匹伐替尼组10.9个月 vs 安慰剂组8.4个月(HR 0.80;P=0.308)。
- PIK3CA+亚组中位无进展生存期卡匹伐替尼组10.9个月 vs 安慰剂组10.8个月(HR 1.11;P=0.760)。
- 根据CTCAE v4.0,卡匹伐替尼组最常见≥3级不良事件为腹泻、高血糖、中性粒细胞减少和斑丘疹。
- 两组紫杉醇剂量强度相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: BEECH investigated the efficacy of capivasertib (AZD5363), an oral inhibitor of AKT isoforms 1-3, in combination with the first-line weekly paclitaxel for advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, and in a phosphoinositide 3-kinase, catalytic, alpha polypeptide mutation sub-population (PIK3CA+). PATIENTS AND METHODS: BEECH consisted of an open-label, phase Ib safety run-in (part A) in 38 patients with advanced breast cancer, and a randomised, placebo-controlled, double-blind, phase II expansion (part B) in 110 women with ER+/HER2- metastatic breast cancer. In part A, patients received paclitaxel 90 mg/m2 (days 1, 8 and 15 of a 28-day cycle) with capivasertib taken twice daily (b.i.d.) at two intermittent ascending dosing schedules. In part B, patients were randomly assigned, stratified by PIK3CA mutation status, to receive paclitaxel with either capivasertib or placebo. The primary end point for part A was safety to recommend a dose and schedule for part B; primary end points for part B were progression-free survival (PFS) in the overall and PIK3CA+ sub-population. RESULTS: Capivasertib was well tolerated, with a 400 mg b.i.d. 4 days on/3 days off treatment schedule selected in part A. In part B, median PFS in the overall population was 10.9 months with capivasertib versus 8.4 months with placebo [hazard ratio (HR) 0.80; P = 0.308]. In the PIK3CA+ sub-population, median PFS was 10.9 months with capivasertib versus 10.8 months with placebo (HR 1.11; P = 0.760). Based on the Common Terminology Criteria for Adverse Event v4.0, the most common grade ≥3 adverse events in the capivasertib group were diarrhoea, hyperglycaemia, neutropoenia and maculopapular rash. Dose intensity of paclitaxel was similar in both groups. CONCLUSIONS: Capivasertib had no apparent impact on the tolerability and dose intensity of paclitaxel. Adding capivasertib to weekly paclitaxel did not prolong PFS in the overall population or PIK3CA+ sub-population of ER+/HER2- advanced/metastatic breast cancer patients.ClinicalTrials.gov: NCT01625286.
引用
- Turner NC, Alarcón E, Armstrong AC, et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019. PMID: 30860570. doi:10.1093/annonc/mdz086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。